Outset Medical
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
On July 7, 2023, Outset Medical made a public disclosure stating that it had received a Warning Letter from the United States Food and Drug Administration (FDA). The letter pointed out that certain materials on the company’s website were promoting the use of continuous renal replacement therapy (CRRT), which is a treatment modality not currently indicated for the Tablo Hemodialysis System. Additionally, the FDA noted that the TabloCart with Prefiltration requires prior 510(k) clearance for marketing authorization.
As a consequence of this news, Outset Medical’s stock price declined by $1.20, representing a 5.9% decrease, and the shares closed at $19.26 per share on July 10, 2023. This decline in stock value resulted in financial losses for investors.
